Philippe Wiesel Email

Chief Medical Officer . AgoMab

Current Roles

Employees:
54
Revenue:
$8.4M
About
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
AgoMab Address
Ghent, BE
Ghent, null
AgoMab Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.